Leveraging its Accelerator™ Drug Development, 360° CDMO and CMO solutions, Thermo Fisher will provide clinical research services for Lyndra’s phase…
Read More
Leveraging its Accelerator™ Drug Development, 360° CDMO and CMO solutions, Thermo Fisher will provide clinical research services for Lyndra’s phase…
Read More— Completion of IND submission for NDI-219216, a non-covalent WRN inhibitor for treatment of MSI-H tumors, with plans to initiate…
Read More